Refractory Marginal Zone Lymphoma

Also known as: Marginal zone lymphoma refractory

Drug	Drug Name	Drug Description
DB15035	Zanubrutinib	A kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy.

Drug	Drug Name	Target	Type
DB15035	Zanubrutinib	Cytochrome P450 3A4	enzyme
DB15035	Zanubrutinib	P-glycoprotein 1	transporter
DB15035	Zanubrutinib	Cytochrome P450 2B6	enzyme
DB15035	Zanubrutinib	Tyrosine-protein kinase BTK	target
DB15035	Zanubrutinib	Epidermal growth factor receptor	target
DB15035	Zanubrutinib	Receptor tyrosine-protein kinase erbB-2	target
DB15035	Zanubrutinib	Receptor tyrosine-protein kinase erbB-4	target
DB15035	Zanubrutinib	Tyrosine-protein kinase ITK/TSK	target
DB15035	Zanubrutinib	Cytoplasmic tyrosine-protein kinase BMX	target
DB15035	Zanubrutinib	Tyrosine-protein kinase JAK2	target
DB15035	Zanubrutinib	Tyrosine-protein kinase Tec	target
DB15035	Zanubrutinib	Tyrosine-protein kinase Blk	target
DB15035	Zanubrutinib	Tyrosine-protein kinase JAK3	target
DB15035	Zanubrutinib	Protein-tyrosine kinase 6	target
DB15035	Zanubrutinib	Tyrosine-protein kinase Fgr	target
DB15035	Zanubrutinib	Tyrosine-protein kinase FRK	target
DB15035	Zanubrutinib	Tyrosine-protein kinase Lck	target
DB15035	Zanubrutinib	Tyrosine-protein kinase TXK	target
DB15035	Zanubrutinib	Cytochrome P450 3A Subfamily	enzyme

Drug	Drug Name	Phase	Status	Count
DB11703	Acalabrutinib	1	Withdrawn	1
DB00928	Azacitidine	1	Active Not Recruiting	1
DB06769	Bendamustine	1	Recruiting	1
DB09052	Blinatumomab	1	Active Not Recruiting	1
DB00531	Cyclophosphamide	1	Recruiting	1
DB11952	Duvelisib	1	Withdrawn	1
DB01073	Fludarabine	1	Recruiting	1
DB06205	Hyaluronidase (human recombinant)	1	Recruiting	1
DB09053	Ibrutinib	1	Active Not Recruiting	2
DB00480	Lenalidomide	1	Active Not Recruiting	3
DB00480	Lenalidomide	1	Recruiting	1
DB00480	Lenalidomide	1	Withdrawn	1
DB00075	Muromonab	1	Active Not Recruiting	1
DB08935	Obinutuzumab	1	Active Not Recruiting	1
DB11759	Pevonedistat	1	Active Not Recruiting	1
DB00073	Rituximab	1	Recruiting	1
DB00135	Tyrosine	1	Withdrawn	1
DB11850	Ublituximab	1	Withdrawn	1
DB14989	Umbralisib	1	Withdrawn	1
DB11581	Venetoclax	1	Recruiting	1
DB02379	Beta-D-Glucose	1 / 2	Active Not Recruiting	1
DB00188	Bortezomib	1 / 2	Completed	1
DB16741	Bortezomib D-mannitol	1 / 2	Completed	1
DB00262	Carmustine	1 / 2	Active Not Recruiting	1
DB00531	Cyclophosphamide	1 / 2	Recruiting	1
DB00987	Cytarabine	1 / 2	Active Not Recruiting	1
DB01234	Dexamethasone	1 / 2	Completed	1
DB00773	Etoposide	1 / 2	Active Not Recruiting	1
DB17573	Evorpacept	1 / 2	Recruiting	1
DB01073	Fludarabine	1 / 2	Recruiting	1
DB00480	Lenalidomide	1 / 2	Completed	1
DB00480	Lenalidomide	1 / 2	Recruiting	1
DB00888	Mechlorethamine	1 / 2	Active Not Recruiting	1
DB14123	Menthol	1 / 2	Completed	1
DB08935	Obinutuzumab	1 / 2	Completed	1
DB00073	Rituximab	1 / 2	Completed	1
DB00073	Rituximab	1 / 2	Recruiting	1
DB00877	Sirolimus	1 / 2	Completed	1
DB06287	Temsirolimus	1 / 2	Completed	1
DB11581	Venetoclax	1 / 2	Active Not Recruiting	1
DB08889	Carfilzomib	2	Terminated	1
DB00531	Cyclophosphamide	2	Recruiting	1
DB00091	Cyclosporine	2	Recruiting	1
DB00099	Filgrastim	2	Recruiting	1
DB01073	Fludarabine	2	Recruiting	1
DB06205	Hyaluronidase (human recombinant)	2	Active Not Recruiting	1
DB00688	Mycophenolate mofetil	2	Recruiting	1
DB01024	Mycophenolic acid	2	Recruiting	1
DB09035	Nivolumab	2	Active Not Recruiting	1
DB15102	Pemigatinib	2	Not Yet Recruiting	1
DB12240	Polatuzumab vedotin	2	Active Not Recruiting	1
DB00073	Rituximab	2	Active Not Recruiting	1
DB00073	Rituximab	2	Terminated	1
DB11678	Treosulfan	2	Recruiting	1
DB11581	Venetoclax	2	Active Not Recruiting	1